ATE420665T1 - Konjugate des granulozyten-kolonie stimulierenden faktors zur gezielten bildgebung von infektionen und entzündungen - Google Patents

Konjugate des granulozyten-kolonie stimulierenden faktors zur gezielten bildgebung von infektionen und entzündungen

Info

Publication number
ATE420665T1
ATE420665T1 AT00913238T AT00913238T ATE420665T1 AT E420665 T1 ATE420665 T1 AT E420665T1 AT 00913238 T AT00913238 T AT 00913238T AT 00913238 T AT00913238 T AT 00913238T AT E420665 T1 ATE420665 T1 AT E420665T1
Authority
AT
Austria
Prior art keywords
inflammations
conjugates
infections
stimulating factor
colony stimulating
Prior art date
Application number
AT00913238T
Other languages
English (en)
Inventor
John Babich
Original Assignee
Molecular Insight Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Insight Pharm Inc filed Critical Molecular Insight Pharm Inc
Application granted granted Critical
Publication of ATE420665T1 publication Critical patent/ATE420665T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00913238T 1999-01-19 2000-01-19 Konjugate des granulozyten-kolonie stimulierenden faktors zur gezielten bildgebung von infektionen und entzündungen ATE420665T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11636499P 1999-01-19 1999-01-19

Publications (1)

Publication Number Publication Date
ATE420665T1 true ATE420665T1 (de) 2009-01-15

Family

ID=22366727

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00913238T ATE420665T1 (de) 1999-01-19 2000-01-19 Konjugate des granulozyten-kolonie stimulierenden faktors zur gezielten bildgebung von infektionen und entzündungen

Country Status (10)

Country Link
US (1) US6491893B1 (de)
EP (1) EP1146913B1 (de)
JP (1) JP4682313B2 (de)
AT (1) ATE420665T1 (de)
AU (1) AU780453B2 (de)
CA (1) CA2359573C (de)
DE (1) DE60041386D1 (de)
DK (1) DK1146913T3 (de)
ES (1) ES2321054T3 (de)
WO (1) WO2000041514A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045116B2 (en) * 2001-12-13 2006-05-16 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals
US7258690B2 (en) 2003-03-28 2007-08-21 Relievant Medsystems, Inc. Windowed thermal ablation probe
US6907884B2 (en) 2002-09-30 2005-06-21 Depay Acromed, Inc. Method of straddling an intraosseous nerve
US8361067B2 (en) 2002-09-30 2013-01-29 Relievant Medsystems, Inc. Methods of therapeutically heating a vertebral body to treat back pain
US20070292354A1 (en) * 2004-09-23 2007-12-20 Guerbet Contrast Agents Encapsulating Systems for Cest Imaging
WO2006050058A2 (en) * 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy of inflamed tissues using immune modulation
EP1933714B1 (de) 2005-09-21 2020-03-18 The Regents of The University of California Systeme und zusammensetzungen für die lokale darstellung und behandlung von schmerzen
EP1940841B9 (de) * 2005-10-07 2017-04-19 Guerbet Verbindungen mit einem eine biologische zielstruktur erkennenden teil, das mit einem zum komplexieren von gallium fähigen signalteil gekoppelt ist
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
EP2339972B1 (de) 2008-09-26 2018-04-11 Relievant Medsystems, Inc. Systeme zur navigation eines instruments durch knochen
US10028753B2 (en) 2008-09-26 2018-07-24 Relievant Medsystems, Inc. Spine treatment kits
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
CN101948550B (zh) * 2010-10-13 2012-05-23 云南万绿生物股份有限公司 高纯度芦荟乙酰化多糖的加工方法
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
AU2012362524B2 (en) 2011-12-30 2018-12-13 Relievant Medsystems, Inc. Systems and methods for treating back pain
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
US9775627B2 (en) 2012-11-05 2017-10-03 Relievant Medsystems, Inc. Systems and methods for creating curved paths through bone and modulating nerves within the bone
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
US9724151B2 (en) 2013-08-08 2017-08-08 Relievant Medsystems, Inc. Modulating nerves within bone using bone fasteners
US9850183B2 (en) 2014-06-27 2017-12-26 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
WO2016111834A1 (en) 2015-01-09 2016-07-14 Reiley Pharmaceuticals, Inc. Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
WO2021050767A1 (en) 2019-09-12 2021-03-18 Relievant Medsystems, Inc. Systems and methods for tissue modulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5032676A (en) 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
US5214132A (en) 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
US5700444A (en) * 1992-02-20 1997-12-23 Rhomed Incorporated Chemotactic peptide pharmaceutical applications
US5108899A (en) * 1989-10-31 1992-04-28 Exoxemis, Inc. Chemiluminescence assay of in vivo inflammation
JPH10509179A (ja) * 1994-11-17 1998-09-08 アムジエン・インコーポレーテツド 安定なｎ−末端結合ｄｔｐａ：蛋白質組成物および方法

Also Published As

Publication number Publication date
WO2000041514A2 (en) 2000-07-20
CA2359573C (en) 2010-04-20
JP4682313B2 (ja) 2011-05-11
EP1146913A2 (de) 2001-10-24
AU780453B2 (en) 2005-03-24
ES2321054T3 (es) 2009-06-02
CA2359573A1 (en) 2000-07-20
US6491893B1 (en) 2002-12-10
DE60041386D1 (de) 2009-03-05
AU3471800A (en) 2000-08-01
DK1146913T3 (da) 2009-05-04
EP1146913B1 (de) 2009-01-14
JP2002534447A (ja) 2002-10-15
WO2000041514A3 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
ATE420665T1 (de) Konjugate des granulozyten-kolonie stimulierenden faktors zur gezielten bildgebung von infektionen und entzündungen
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
DE69934337D1 (de) Konjugate zur Behandlung von Entzündungskrankheiten und von assozierter Gewebeschädigung
PE20001112A1 (es) Derivados de quinolina como agentes antibacterianos
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
BRPI0411078A (pt) ligantes de receptores de canabinóides e seus usos
DK1189634T3 (da) Behandling af prostatacancer med anti-ErbB2-antistoffer
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
MA27929A1 (fr) Utilisation de calcitonine pour le traitement de l'osteoarthrite
TR200201484T2 (tr) Çeşitli hastalıkların koruyucu ve iyileştirici tedavisi için bakteriyel fajlar ile ilişkili lisleme enzimlerinin kullanımı
TR200003170T2 (tr) MRS inhibitörleri ve bakterisid olarak kullanılan quinolone'lar
ATE224386T1 (de) Neue in 6-position substituierte phenanthridine
ATE355288T1 (de) Verbindungen und therapeutische methoden
SE9904377D0 (sv) Pharmaceutical combinations
HK1036222A1 (en) Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives.
DE60324179D1 (de) Chinoline und stickstoffhaltige derivatedavon und deren verwendung als antibakterielle mittel
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
NO20005548D0 (no) Mykobakterieinhibitorer
PT1606233E (pt) Derivados de esteres lipidicos de nucleotidos
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários
BR9914722A (pt) Derivados de anticonvulsivo úteis no tratamento de dependência, vìcio e abuso do álcool
ATE321760T1 (de) N-aryl-2-oxazolidinone und deren derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1146913

Country of ref document: EP